We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Health insurer UnitedHealth Group Inc. (UNH - Free Report) has renewed its long-term strategic partnership with LabCorp, a leading global life sciences company providing comprehensive clinical laboratory and end-to-end drug development services.
Per the agreement, LabCorp will continue to serve as UnitedHealthcare’s exclusive national laboratory provider till Jan 1, 2019. However, effective this date, Quest Diagnostics will become an “in network” lab for more than 48 million enrollees covered under the UnitedHealthcare plans. UnitedHealth has entered into a long-term agreement with Quest Diagnostic for the same.
Via these agreements, UnitedHealth intends to bring the accountable care arrangements (ACOs) model of payments to the diagnostic companies. Both companies will together provide a variety of value-based programs, with the same aligned incentives and enhanced patient experience to lab services, like what we see in accountable care arrangements with UnitedHealthcare and more than 1,100 hospitals and 110,000 physicians.
This would result in payment based on final outcome and quality of care provided compared with fee for service, which emphasized volume of care rather than quality.
Under the fee-for-service model, unnecessary lab tests were prescribed by physicians which resulted in high reimbursement from insurance companies. A shift to value-based care is the need of the hour to make the healthcare system more efficient and reduce medical cost.
UnitedHealth expects that within 10 years, half of all Americans will be receiving health care from physicians operating in highly evolved and coordinated value-based care designs because the outcome clearly demonstrates improved quality and consumer satisfaction while reducing the cost of health care. The company is working toward this structural shift from fragmented fee for service.
Year to date the stock has gained 10.5% compared with the industry’s growth of 7.8%.
Value-based reimbursement of services has gradually gained ground, but now all the major players Aetna Inc. , Humana Inc. (HUM - Free Report) , Cigna Corp. (CI - Free Report) are moving full speed ahead.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
UnitedHealth Extends LabCorp Ties, Signs Quest Diagnostic Deal
Health insurer UnitedHealth Group Inc. (UNH - Free Report) has renewed its long-term strategic partnership with LabCorp, a leading global life sciences company providing comprehensive clinical laboratory and end-to-end drug development services.
Per the agreement, LabCorp will continue to serve as UnitedHealthcare’s exclusive national laboratory provider till Jan 1, 2019. However, effective this date, Quest Diagnostics will become an “in network” lab for more than 48 million enrollees covered under the UnitedHealthcare plans. UnitedHealth has entered into a long-term agreement with Quest Diagnostic for the same.
Via these agreements, UnitedHealth intends to bring the accountable care arrangements (ACOs) model of payments to the diagnostic companies. Both companies will together provide a variety of value-based programs, with the same aligned incentives and enhanced patient experience to lab services, like what we see in accountable care arrangements with UnitedHealthcare and more than 1,100 hospitals and 110,000 physicians.
This would result in payment based on final outcome and quality of care provided compared with fee for service, which emphasized volume of care rather than quality.
Under the fee-for-service model, unnecessary lab tests were prescribed by physicians which resulted in high reimbursement from insurance companies. A shift to value-based care is the need of the hour to make the healthcare system more efficient and reduce medical cost.
UnitedHealth expects that within 10 years, half of all Americans will be receiving health care from physicians operating in highly evolved and coordinated value-based care designs because the outcome clearly demonstrates improved quality and consumer satisfaction while reducing the cost of health care. The company is working toward this structural shift from fragmented fee for service.
Year to date the stock has gained 10.5% compared with the industry’s growth of 7.8%.
Value-based reimbursement of services has gradually gained ground, but now all the major players Aetna Inc. , Humana Inc. (HUM - Free Report) , Cigna Corp. (CI - Free Report) are moving full speed ahead.
UnitedHealth carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>